ImmunityBio Faces Securities Fraud Class Action Over Cancer Drug ClaimsMay 4, 2026Law and PolicyA securities fraud class action filed against ImmunityBio targets executive Patrick Soon-Shiong's claim that cancer drug Anktiva is a vaccine, a description the FDA rejected.